News
If you’re benchmarking or experiencing performance problems in your React apps, make sure you’re testing with the minified production build.
![Fibralign Sponsors International Research Seminar](https://www.fibralignbio.com/wp-content/uploads/2022/01/lymphedema-summit-banner-1080x675.jpg)
Fibralign Sponsors International Research Seminar
Fibralign is hosting the inaugural Lymphedema Summit on January 23- Fibralign is hosting the inaugural Lymphedema Summit on January 23, an international research seminar focused on “Advancements in Lymphedema Surgical Treatment.” For more details:...
![Fibralign Selected as a UCSF Rosenman Institute Innovator](https://www.fibralignbio.com/wp-content/uploads/2021/06/Rosenman-Innovator-Fibralign-new.png)
Fibralign Selected as a UCSF Rosenman Institute Innovator
NCI-funded study evaluating Fibralign’s BioBridge® as an adjunct to microsurgical treatment SAN FRANCISCO, June 10, 2021 /PRNewswire/ -- The UCSF Rosenman Institute is proud to announce the 2021 cohort of the Rosenman Innovators, a group of early-stage health...
![UChicago Medicine Enrolling Patients in Lymphbridge™ Clinical Study For Surgical Treatment Of Breast Cancer-Related Lymphedema](https://www.fibralignbio.com/wp-content/uploads/2021/04/uchicago-1.png)
UChicago Medicine Enrolling Patients in Lymphbridge™ Clinical Study For Surgical Treatment Of Breast Cancer-Related Lymphedema
NCI-funded study evaluating Fibralign’s BioBridge® as an adjunct to microsurgical treatment April 14, 2021 – The University of Chicago Medicine has announced today that it is now enrolling patients into LymphBridge™, a randomized clinical study to evaluate a...
![Fibralign Announces Start of European Lymphedema Prevention Clinical Study](https://www.fibralignbio.com/wp-content/uploads/2021/02/eu.png)
Fibralign Announces Start of European Lymphedema Prevention Clinical Study
Multi-site clinical study to evaluate BioBridge® as prophylactic treatment for at-risk patients UNION CITY, Calif.--(BUSINESS WIRE)--Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced enrollment of the first...
![Fibralign Announces CE Mark Approval for BioBridge®](https://www.fibralignbio.com/wp-content/uploads/2020/09/ce-mark-image.jpeg)
Fibralign Announces CE Mark Approval for BioBridge®
European approval for novel device supporting surgical treatment of lymphedema September 14, 2020 (Union City, CA) – Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first...
![Fibralign Announces Strategic Partnership with Terumo](https://www.fibralignbio.com/wp-content/uploads/2020/06/terumo-medical-corporation-logo-vector.png)
Fibralign Announces Strategic Partnership with Terumo
Exclusive agreement for Terumo to market and distribute Fibralign’s BioBridge in Japan June 02, 2020 06:00 AM Eastern Daylight Time UNION CITY, Calif.--(BUSINESS WIRE)--Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced...
![Fibralign Awarded SBIR Phase IIS from Department of Defense](https://www.fibralignbio.com/wp-content/uploads/2019/01/Default-DHA-Logo.jpg)
Fibralign Awarded SBIR Phase IIS from Department of Defense
Fibralign announced today that it has been awarded a Small Business Innovation Research (SBIR) Sequential Phase II (Phase IIS) from the Department of Defense (DoD) Defense Health Program (DHP). This two-year grant provides $996,609 in funding to continue advancing...
![Fibralign receives ISO 13485:2016 upgrade certification](https://www.fibralignbio.com/wp-content/uploads/2019/01/346_main.jpg)
Fibralign receives ISO 13485:2016 upgrade certification
Fibralign received Certification Notification on January 21, 2019 from DEKRA Certification B. V. that the Company's management system meets the requirements of EN ISO 13486:2016. This internationally agreed standard sets out the requirements for a quality management...